Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: Results from a systematic review and exploratory meta-analysis

Expert Opinion on Drug Safety

Volumn 14, Issue 10, 2015, Pages 1587-1608

  Galling, Britta ^a   Calsina Ferrer, Amat ^b   Abi Zeid Daou, Margarita ^c   Sangroula, Dinesh ^a   Hagi, Katsuhiko ^a,d   Correll, Christoph U ^a,e,f,g  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b Santa Caterina Hospital   (Spain)

^c Psychiatric Hospital at Vanderbilt   (United States)

^d DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^e DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^f FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

adverse effects; antidepressant; augmentation; co treatment; combination; depression; major depressive disorder; meta analysis; safety; tolerability

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE UPTAKE INHIBITOR; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; NORADRENERGIC AND SPECIFIC SEROTONERGIC ANTIDEPRESSANT; NOREPINEPHRINE DOPAMINE REUPTAKE INHIBITOR; SEROTONIN ANTAGONIST AND REUPTAKE INHIBITOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANESTHESIA COMPLICATION; BODY WEIGHT DISORDER; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; HOSPITAL PATIENT; HUMAN; MAJOR DEPRESSION; META ANALYSIS; MONOTHERAPY; OUTPATIENT; REVIEW; SEDATION; SWEAT GLAND DISEASE; SWEATING; SYSTEMATIC REVIEW; TREMOR; WEIGHT GAIN; XEROSTOMIA; ACUTE DISEASE; ADULT; COMBINATION DRUG THERAPY; DEPRESSIVE DISORDER, MAJOR;

ACUTE DISEASE; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; HUMANS;

EID: 84942296148     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1085970     Document Type: Review

References (66)

1. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder [Internet]. American Psychiatric Association, Washington, DC; 2010. Available from: http://psychiatryonline.com. [Last accessed 8 May 2015]
2. National Institute for Health and Clinical Excellence. Depression: The treatment and management of depression in adults (G90). National Institute for Health and Care Excellence; 2009. Available from: https://www.nice.org.uk/guidance/cg91/resources/guidance-depression-in-adults-with-a-chronic-physical-health-problem-pdf. [Last accessed 1 September 2015]
3. Härter M, Klesse C, Bermejo I, et al. Unipolar depression: diagnostic and therapeutic recommendations from the current S3/National Clinical Practice Guideline. Dtsch Ärztebl Int 2010; 107 (40): 700-8
4. Kennedy SH, Eisfeld BS, Meyer JH, Bagby RM. Antidepressants in clinical practice: limitations of assessment methods and drug response. Hum Psychopharmacol 2001; 16 (1): 105-14
5. Nemeroff CB, Entsuah R, Benattia I, et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 2008; 63 (4): 424-34
6. Bowden CL, Schatzberg AF, Rosenbaum A, et al. Fluoxetine and desipramine in major depressive disorder. J Clin Psychopharmacol 1993; 13 (5): 305-11
7. Tignol J. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol 1993; 13 (6 Suppl 2): 18S-22S
8. Ansseau M, Papart P, Troisfontaines B, et al. Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology (Berl) 1994; 114 (1): 131-7
9. Bennie EH, Mullin JM, Martindale JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 1995; 56 (6): 229-37
10. Valenstein M, McCarthy JF, Austin KL, et al. What happened to lithium? Antidepressant augmentation in clinical settings. Am J Psychiatry 2006; 163 (7): 1219-25
11. Köhler S, Unger T, Hoffmann S, et al. Comparing augmentation with non-antidepressants over sticking to antidepressants after treatment failure in depression: a naturalistic study. Pharmacopsychiatry 2013; 46 (2): 69-76
12. Blier P, Gobbi G, Turcotte JE, et al. Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009; 19 (7): 457-65
13. Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010; 167 (3): 281-8
14. Maes M, Libbrecht I, van Hunsel F, et al. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol 1999; 19 (2): 177-82
15. Fava M, Alpert J, Nierenberg A, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 2002; 22 (4): 379-87
16. Dodd S, Horgan D, Malhi GS, Berk M. To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord 2005; 89 (1-3): 1-11
17. Fleurence R, Williamson R, Jing Y, et al. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull 2009; 42 (3): 57-90
18. Chang C-M, Sato S, Han C. Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression. CNS Drugs 2013; 27 (Suppl 1): S21-7
19. De la Gándara J, Aguëra L, Rojo JE, et al. Use of antidepressant combinations: which, when and why? Results of a Spanish survey. Acta Psychiatr Scand 2005; 112: 32-5
20. Zimmerman M, Posternak M, Friedman M, et al. Which Factors Influence Psychiatrists Selection of Antidepressants? Am J Psychiatry 2004; 161 (7): 1285-9
21. Rocha FL, Fuzikawa C, Riera R, Hara C. Combination of antidepressants in the treatment of major depressive disorder: A systematic review and meta-analysis. J Clin Psychopharmacol 2012; 32 (2): 278-81
22. Lopes Rocha F, Fuzikawa C, Riera R, et al. Antidepressant combination for major depression in incomplete responders-A systematic review. J Affect Disord 2013; 144 (1-2): 1-6
23. Connolly KR, Thase ME. If at first you dont succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011; 71 (1): 43-64
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7 (3): 177-88
25. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315 (7109): 629-34
26. Duval S, Tweedie R. A Nonparametric "Trim and Fill" Method of Accounting for Publication Bias in Meta-Analysis. J Am Stat Assoc 2000; 95 (449): 89-98
27. Akkaya C, Kirli S, Eker SS, et al. Comparison of the efficacy and safety of sertraline, reboxetine, and venlafaxine in patients with major depressive disorder: A pooled analysis of four randomized, open-label trials. Klin Psikofarmakol Bül Bull Clin Psychopharmacol 2010; 20 (4): 274-87
28. Ball S, Dellva MA, DSouza DN, et al. A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment. J Affect Disord 2014; 167: 215-23
29. Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): Acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011; 168 (7): 689-701
30. Dam J, Ryde L, Svejsø J, et al. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. Pharmacopsychiatry 1998; 31 (2): 48-54
31. Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994; 151 (9): 1372-4
32. Ferreri M, Lavergne F, Berlin I, et al. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand 2001; 103 (1): 66-72
33. Fornaro M, Martino M, Mattei C, et al. Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol 2014; 24 (8): 1269-78
34. Gulrez G, Badyal DK, Deswal RS, Sharma A. Bupropion as an augmenting agent in patients of depression with partial response. Basic Clin Pharmacol Toxicol 2012; 110 (3): 227-30
35. Lauritzen L, Clemmesen L, Klysner R, et al. Combined treatment with imipramine and mianserin: A controlled pilot study. Pharmacopsychiatry 1992; 25 (4): 182-6
36. Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment: A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berl) 2002; 161 (2): 143-51
37. Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J Affect Disord 1996; 41 (3): 201-10
38. Matreja PS, Badyal DK, Deswal RS, Sharma A. Efficacy and safety of add on low-dose mirtazapine in depression. Indian J Pharmacol 2012; 44 (2): 173-7
39. Murphy JE. A comparative trial of Anafranil, Pertofran and an Anafranil/Pertofran combination. J Int Med Res 1977; 5 (1 Suppl): 16-23
40. Nelson JC, Mazure CM, Jatlow PI, et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004; 55 (3): 296-300
41. OBrien S, McKeon P, ORegan M, et al. Blood pressure effects of tranylcypromine when prescribed singly and in combination with amitriptyline. J Clin Psychopharmacol 1992; 12 (2): 104-9
42. Raisi FR, Habibi N, Nasehi AA, Mohammadi MR. Combination of Citalopram and Nortriptyline in Treatment of Moderate to Severe Major Depression: A Double-blind, Placebo-controlled Trial. Iran J Psychiatry 2006; 1 (1): 35-8
43. Stewart JW, McGrath PJ, Blondeau C, et al. Combination antidepressant therapy for major depressive disorder: speed and probability of remission. J Psychiatr Res 2014; 52: 7-14
44. Vezmar S, Miljkovic B, Vucicevic K, et al. Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression. J Pharmacol Sci 2009; 110 (1): 98-104
45. Young JP, Lader MH, Hughes WC. Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. Br Med J 1979; 2 (6201): 1315-17
46. Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002; 51 (2): 183-8
47. Galling B, Garcia MA, Osuchukwu U, et al. Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis. Expert Opin Drug Saf 2015; 1-19
48. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005; 352 (11): 1112-20
49. Decoutere L, De Winter S, Vander Weyden L, et al. A venlafaxine and mirtazapine-induced serotonin syndrome confirmed by de-and re-challenge. Int J Clin Pharm 2012; 34 (5): 686-8
50. Talarico G, Tosto G, Pietracupa S, et al. Serotonin toxicity: a short review of the literature and two case reports involving citalopram. Neurol Sci 2011; 32 (3): 507-9
51. Schellander R, Donnerer J. Antidepressants: clinically relevant drug interactions to be considered. Pharmacology 2010; 86 (4): 203-15
52. Paslakis G, Gilles M, Deuschle M. Clinically relevant pharmacokinetic interaction between venlafaxine and bupropion: a case series. J Clin Psychopharmacol 2010; 30 (4): 473-4
53. Hori H, Yoshimura R, Ueda N, et al. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder. World J Biol Psychiatry 2009; 10 (4 Pt 2): 620-2
54. Vlase L, Leucuta A, Farcau D, Nanulescu M. Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. Biopharm Drug Dispos 2006; 27 (6): 285-9
55. Sennef C, Timmer CJ, Sitsen JMA. Mirtazapine in combination with amitriptyline: a drug-drug interaction study in healthy subjects. Hum Psychopharmacol 2003; 18 (2): 91-101
56. Purgato M, Papola D, Gastaldon C, et al. Paroxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2014; 4: CD006531
57. Magni LR, Purgato M, Gastaldon C, et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 2013; 7: CD004185
58. Cipriani A, Koesters M, Furukawa TA, et al. Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2012; 10: CD006533
59. Cipriani A, Purgato M, Furukawa TA, et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2012; 7: CD006534
60. Cipriani A, La Ferla T, Furukawa TA, et al. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev 2010 (4): CD006117
61. Omori IM, Watanabe N, Nakagawa A, et al. Fluvoxamine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2010 (3): CD006114
62. Watanabe N, Omori IM, Nakagawa A, et al. MANGA (Meta-Analysis of New Generation Antidepressants) Study Group. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs 2010; 24 (1): 35-53
63. Nakagawa A, Watanabe N, Omori IM, et al. Milnacipran versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009 (3): CD006529
64. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet Lond Engl 2009; 373 (9665): 746-58
65. Kovacs D, Gonda X, Petschner P, et al. Antidepressant treatment response is modulated by genetic and environmental factors and their interactions. Ann Gen Psychiatry 2014; 13: 17
66. Fabbri C, Porcelli S, Serretti A. From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment. Can J Psychiatry Rev Can Psychiatr 2014; 59 (2): 62-75